This site is intended for healthcare professionals
Search

Find disease awareness content and relevant supporting materials

Learning Zone 327 Events 46 News 16860 Drugs 53740 Trials 7873 Guidelines 846 Journals 3335
Filter results
Sort by:
Relevance
to
Journals
Journal
21/03/16

Clinical effectiveness and safety of powered exoskeleton-assisted walking in patients with spinal cord injury: systematic review with meta-analysis.

Background: Powered exoskeletons are designed to safely facilitate ambulation in patients with spinal cord injury (SCI). We conducted the first meta-analysis of the available published research on the clinical effectiveness and safety of powered exoskeletons in SCI patients.

  • 1 min read
  • Source: Medical Devices: Evidence and Research
Latest drug news
Drug news
23/04/16

Meta analysis of literature of efficacy and safety of exoskeleton-assisted walking in patients with spinal cord injury.- ReWalk Robotics Ltd.

ReWalk Robotics Ltd. announced the publication of the first systematic review and industry-wide meta-analysis of existing published literature assessing the...

  • 1 min read
Latest drug news
Drug news
22/06/12

FDA approves Lyrica (Pfizer) for management of pain associated with Spinal Cord Injury

The FDA has approved the use of Lyrica (pregabalin) capsules CV from Pfizer for the management of Neuropathic Pain associated...

  • 1 min read
Clinical trials
Clinical trial
06/11/13

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 2 Years to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

In children with a severe form of spina bifida (which is the consequence of a spinal cord defect) it can...

  • 1 min read
  • Source: Clinicaltrials.gov
Guidelines
Guideline
17/02/16

Spinal injury: assessment and initial management

This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres.

  • 1 min read
  • Source: National Institute for Health and Care Excellence (NICE)
Latest drug news
Drug news
10/06/22

EU gives positive opinion on Dysport in urinary incontinence.

Ipsen announced that Dysport (abobotulinumtoxinA) has received positive opinion in Europe for the management of urinary incontinence (UI) in adults with neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) (traumatic or non-traumatic) or multiple sclerosis (MS), who are regularly performing clean intermittent catheterization (CIC).

  • 1 min read
Latest drug news
Drug news
29/03/12

Allergan seeks wider indication at FDA/EU for Botox for Overactive Bladder

Allergan has submitted a supplemental BLA with the US FDA and an application with European regulatory authorities seeking approval of...

  • 1 min read
Latest drug news
Drug news
10/03/23

Topline data announced from pivotal INSPIRE 2.0 study of Neuro-Spinal Scaffold for acute spinal cord injury.-InVivo Therapeutics

InVivo Therapeutics Holdings Corp. a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI),announced topline results from the company's INSPIRE 2.0 tudy, which was designed to evaluate the safety and probable benefit of InVivo's investigational Neuro-Spinal Scaffold, a bioresorbable scaffold-based device in development for patients with acute SCI.

  • 1 min read
Clinical trials
Clinical trial
17/11/11

Clinical Value of Homeopathic Prophylaxis of Recurrent Urinary Tract Infections in Persons With Spinal Cord Injury

Recurrent symptomatic urinary tracts infections (UTI) in persons with spinal cord injury are a frequent problem, leading to significant morbidity...

  • 1 min read
  • Source: Clinicaltrials.gov
Latest drug news
Drug news
03/10/12

Botox (Allergan) approved by MHRA in UK for Urinary Incontinence

The Medicines and Healthcare products Regulatory Agency (MHRA)in the UK has given Botox (botulinum toxin type A) approval for managing...

  • 1 min read
See more